Sally Church - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Sally Church

Sally Church

Creator
0 followers

Oncology consultant and blogger; author of PharmaStrategy Blog known for insightful analysis of cancer drug development.

Recent Posts

European ADC Agents with Novel Targets Gain Momentum
Social•Feb 17, 2026

European ADC Agents with Novel Targets Gain Momentum

With all the attention on China for TOPO-I ADCs of late, how about the potential for European agents, especially ones involving novel targets? Our latest expert interview drops with some hard hitting and candid opinions from a battle hardened CSO... https://t.co/NuUHHBsLV7 https://t.co/EZd8iawO0G

By Sally Church
Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns
Social•Jan 9, 2026

Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns

It's good to see new trial readouts at #GI26, although there are 7 reasons to be bearish about the zanidatamab data in gastric cancer: https://t.co/g2MbrPI7Iu https://t.co/tBY2yJ6YMe

By Sally Church
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
Social•Jan 8, 2026

Zanidatamab Plus Tislelizumab Raises Diarrhea Risk

#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx

By Sally Church